- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | iSpecimen Inc.: iSpecimen Named Top Competitor in $4.4 Billion USD Market | 194 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| Do | iSpecimen Inc: iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually | 2 | GlobeNewswire (USA) | ||
| Do | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 31.10. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.10. | iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 30.10. | iSpecimen sets $5 million public stock offering at $3 per share | 2 | Investing.com | ||
| 30.10. | iSpecimen setzt öffentliches Aktienangebot von 5 Millionen US-Dollar zu 3 US-Dollar pro Aktie fest | 2 | Investing.com Deutsch | ||
| 30.10. | iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 18.10. | iSpecimen files to sell 1.2M shares of common stock | 2 | Seeking Alpha | ||
| 18.10. | iSpecimen Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 02.10. | iSpecimen Regains Nasdaq compliance, faces arbitration claim | 1 | Investing.com | ||
| 26.09. | iSpecimen secures $1 million loan, revamps board | 1 | Investing.com | ||
| 26.09. | iSpecimen sichert sich Darlehen über 1 Million US-Dollar und strukturiert Vorstand um | 5 | Investing.com Deutsch | ||
| 26.09. | iSpecimen Inc: iSpecimen Secures $1 Million Loan; Appoints Three New Board Members | 1 | GlobeNewswire (USA) | ||
| 25.09. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.09. | ISpecimen Down 19% In Pre-market Following Reverse Stock Split | 2 | RTTNews | ||
| 11.09. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | iSpecimen announces 1-for-20 reverse stock split | 1 | Seeking Alpha | ||
| 11.09. | iSpecimen Inc: iSpecimen Announces 1-for-20 Reverse Stock Split | 120 | GlobeNewswire (Europe) | WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical... ► Artikel lesen | |
| 06.08. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,000 | +24,07 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| ILLUMINA | 139,98 | -0,70 % | Illumina-Aktie mit großen Kursgewinnen (142,2005 €) | Die Aktie von Illumina zählt am Montag zu den großen Gewinnern an der Börse. Der Titel verteuert sich heute deutlich. Zu den auffälligsten Aktien am US-amerikanischen Aktienmarkt gehört heute der Anteilsschein... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,200 | +0,21 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | -CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 15,850 | +1,73 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress | Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on... ► Artikel lesen | |
| EDITAS MEDICINE | 2,978 | +2,16 % | Editas Medicine, Inc.: Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,383 | -4,25 % | Defence Therapeutics meldet Verlängerung der Privatplatzierung und setzt die Entwicklung seiner Radiopharmazeutika- und ADC-Programme fort | Vancouver, BC, Kanada, 4. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das
"Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches Unternehmen... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 115,00 | -1,92 % | Neurocrine Biosciences Aktie: Gute Aussichten! | ||
| BLUEBIRD BIO | 0,387 | +0,34 % | bluebird bio expands incentive plan amid leadership changes | ||
| GALAPAGOS NV | 25,100 | -0,40 % | Galapagos NV: Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 | New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 20,000 | -2,10 % | Arrowhead targets rare disease patients, pushing message that hope is on the horizon | ||
| GINKGO BIOWORKS | 7,600 | -4,40 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,750 | -4,18 % | Cardiff Oncology Inc reports results for the quarter ended in September 30 - Earnings Summary | ||
| TWIST BIOSCIENCE | 42,160 | -0,43 % | Twist Bioscience CEO Emily Leproust verkauft Aktien im Wert von 639.368 US-Dollar | ||
| REPLIGEN | 134,45 | +2,44 % | Repligen Corporation: Repligen Reports Second Quarter 2024 Financial Results | Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,100 | +2,45 % | Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M |
Das Unternehmen ISPECIMEN INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,890 Euro und damit -1,01 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.
